NCT06096688 Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
| NCT ID | NCT06096688 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Weill Medical College of Cornell University |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,120 participants |
| Start Date | 2019-05-29 |
| Primary Completion | 2026-05-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,120 participants in total. It began in 2019-05-29 with a primary completion date of 2026-05-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and/or endometrial cancer at NYPH and WCM for routine clinical care and to make these available for future use for molecular and mechanistic studies.
Eligibility Criteria
The following eligibility criteria must be met as follows: 1. Age ≥ 18 years old. 2. One of the following must be met: 1. Diagnosis of a Hereditary Cancer Syndrome by positive genetic testing and/or clinical criteria to undergo an endoscopy procedure (esophagoduodenoscopy and/or colonoscopy/flexible sigmoidoscopy), or endometrial screening procedure (transvaginal ultrasound and/or hysteroscopy and/or endometrial biopsy), OR 2. Individuals coming to Weill-Cornell Medicine/NYPH to undergo an endoscopy procedure, transvaginal ultrasound, or hysteroscopy for average-risk (population-based) recommendation OR 3. Individuals diagnosed with colorectal cancer or endometrial cancer coming to Weill- Cornell Medicine/NYPH for surgical treatment OR 4. Individuals coming to Weill-Cornell Medicine/NYPH for care such as, but not limited to, diagnostic testing, clinic and/or treatment visit. 3. Willingness and ability to sign informed consent. 4. Ability to read/understand English, Spanish, and/or simplified Chinese.
Contact & Investigator
Steven M Lipkin, MD
PRINCIPAL INVESTIGATOR
Weill Medical College of Cornell University
Frequently Asked Questions
Who can join the NCT06096688 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06096688 currently recruiting?
Yes, NCT06096688 is actively recruiting participants. Contact the research team at stl2012@med.cornell.edu for enrollment information.
Where is the NCT06096688 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06096688 clinical trial?
NCT06096688 is sponsored by Weill Medical College of Cornell University. The principal investigator is Steven M Lipkin, MD at Weill Medical College of Cornell University. The trial plans to enroll 1,120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.